Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- SHINE-2 (NCT05784246)
- Testing
- Mirikizumab IV, Mirikizumab SC
- Where
- 34 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis (UC), UC - Ulcerative Colitis
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT06850727
- Testing
- OD-07656, Vedolizumab
- Where
- 32 sites in Australia, Austria and 8 more
- Volunteers
- 57 people
- Sponsor
- Odyssey Therapeutics, Inc.
Ulcerative Colitis (UC)
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.
- Trial name
- NCT05377580
- Testing
- Period 2 IBI112 dose 3, Period 1 IBI112 dose 1, Period 1 IBI112 dose 2
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Colitis, Ulcerative
GSK2982772 Study in Subjects With Ulcerative Colitis
This study is the first experience with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with active ulcerative colitis (UC).
- Trial name
- NCT02903966
- Testing
- GSK2982772
- Where
- 23 sites in United States, Germany and 5 more
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine
- Trial name
- PROTECT-3 (NCT02849951)
- Testing
- LT-02
- Where
- 45 sites in United States
- Volunteers
- 25 people
- Sponsor
- Prometheus Laboratories
Colitis, Ulcerative
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HX15001 injection combined with Etrasimod tablets in participants with moderately to severely active ulcerative…
- Trial name
- NCT07768254
- Testing
- Biological: HX15001
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Ulcerative Colitis, Inflammatory Bowel Disease
Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy…
- Trial name
- NCT00038922
- Testing
- rhIL-11
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ulcerative Colitis, Inflammatory Bowel Diseases
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
- Trial name
- Aegean (NCT07513181)
- Testing
- ATH-063
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Athos Therapeutics Inc
Ulcerative Colitis
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).
- Trial name
- NCT00573794
- Testing
- adalimumab
- Volunteers
- 592 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis
- Trial name
- NCT00449722
- Testing
- mesalazine
- Where
- Germany
- Volunteers
- 380 people
- Sponsor
- Dr. Falk Pharma GmbH
Colitis, Ulcerative
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis.
- Trial name
- ENDEAVOUR-UC (NCT06398626)
- Testing
- Etrasimod
- Where
- 29 sites in United States
- Volunteers
- 300 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis.
- Trial name
- NCT07083193
- Testing
- AC-101
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Ulcerative Colitis
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment…
- Trial name
- NCT05118919
- Testing
- BGP-014
- Where
- 4 sites in Sweden
- Volunteers
- 35 people
- Sponsor
- BioGaia Pharma AB
Ulcerative Colitis
Basiliximab in Moderate to Severe Ulcerative Colitis
The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
- Trial name
- NCT00430898
- Testing
- Basiliximab
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 181 people
- Sponsor
- Cerimon Pharmaceuticals
Ulcerative Colitis
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT02531126
- Testing
- RPC1063
- Where
- 41 sites in United States, Australia and 18 more
- Volunteers
- 877 people
- Sponsor
- Celgene
Ulcerative Colitis
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.
- Trial name
- NCT00446849
- Testing
- MMX Mesalamine
- Where
- 62 sites in United States
- Volunteers
- 290 people
- Sponsor
- Shire
Colitis, Ulcerative
Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of PF-06480605 in subjects with moderate to severe ulcerative colitis.
- Trial name
- NCT02840721
- Testing
- PF-06480605
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 50 people
- Sponsor
- Telavant, Inc.
Ulcerative Colitis (UC)
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of…
- Trial name
- COMMAND (NCT03398135)
- Testing
- risankizumab
- Where
- 426 sites in United States, Argentina and 41 more
- Volunteers
- 1,242 people
- Sponsor
- AbbVie
Ulcerative Colitis
Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis
This Phase I study will be a closely monitored trial of a small number of subjects to establish, preliminarily, the tolerability and safety of two ALTH12 enema formulations: ALTH12-1:4 and ALTH12-2:4.
- Trial name
- NCT01020708
- Testing
- mesalamine, ALTH12-1:4, ALTH12-2:4
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Altheus Therapeutics, Inc.
Crohn Disease, Ulcerative Colitis
Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease
The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in patients with ulcerative colitis and Crohn disease.
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT07383597
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Efferon JSC